Erytech Pharma EBIT

Erytech Pharma (ERYP) currently reports a EBIT of $-2.8M as of December 2022. That compares with $-57M in the prior-year period — up 95.1% year over year. That is below the Healthcare sector average of $22B. Use the charts on this page to explore Erytech Pharma's EBIT history and peer comparisons.

Erytech Pharma's EBIT increased from $-57M to $-2.8M — a 95.1% year-over-year increase (period ending December 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Erytech Pharma's EBIT of $-2.8M is lower than the Healthcare sector average of $22B. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Erytech Pharma reported $-2.8M in EBIT as of December 2022. That compares with $-57M in the prior-year period — up 95.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-2.8M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $22B. From there, open related valuation or income-statement pages for Erytech Pharma, and consider following ERYP for alerts when major investors trade the stock.